Eingang zum Volltext in SciDok

Hinweis zum Urheberrecht

Aufsatz zugänglich unter
URN: urn:nbn:de:bsz:291-scidok-15384

Serological immune response to cancer testis antigens in patients with pancreatic cancer

Wadle, Andreas ; Kubuschok, Boris ; Imig, Jochen ; Wuellner, Beate ; Wittig, Christine ; Zwick, Carsten ; Mischo, Axel ; Waetzig, Katrin ; Romeike, Bernd F. M. ; Lindemann, Werner ; Schilling, Martin ; Pfreundschuh, Michael ; Renner, Christoph

Quelle: (2006) International journal of cancer. - 119. 2006, 1, S. 117-125
Dokument 1.pdf (380 KB)

Bookmark bei Connotea Bookmark bei
Institut 1: Fachrichtung 2.7 - Innere Medizin
Institut 2: Fachrichtung 2.9 - Chirurgie
Institut 3: Fachrichtung 2.22 - Pathologie
DDC-Sachgruppe: Medizin
Dokumentart: Aufsatz
Sprache: Deutsch
Erstellungsjahr: 2006
Publikationsdatum: 15.05.2008
Kurzfassung auf Englisch: Serological screening approaches have allowed for the identification of a large number of potentially relevant tumor antigens in cancer patients. Within this group, cancer testis antigens represent promising targets for cancer immunotherapy, since they are widely expressed in a variety of human cancer entities. In pancreatic cancer, however, there are only few data available about the expression pattern and serological response to cancer testis antigens and other serological-defined tumor antigens. Therefore, we investigated the IgG antibody response against 11 cancer testis antigens (SCP-1, GAGE, LAGE-1a,-1b, CT-7, NY-ESO-1, SSX-1-5) recombinantly expressed on yeast surface (RAYS) in patients with pancreatic cancer (n = 96), chronic pancreatitis (n = 18) and healthy donors (n = 48). We found in 14% of all patients antibody responses to SCP-1, but not to other cancer testis antigens (GAGE, LAGE-1a,-1b, CT-7, NY-ESO-1, SSX-1-5). Antibody response correlated with the expression of SCP-1 in the primary tumor of the respective patient as shown by RT-PCR, immunohistochemistry and Western blot. In contrast, no serological response to cancer testis antigens was observed in healthy donors. The humoral immune response against SCP-1 was associated with the size of tumor, but not with other clinico-pathological parameters such as histology, stage, presence of lymph node metastases, grading, age, gender or gemcitabine treatment. In conclusion, antibody response to cancer testis antigen SCP-1 is found in a proportion of pancreatic carcinoma patients. These results indicate that identification of additional tumor antigens by serological screening of tumor cDNA expression libraries by RAYS is a promising goal in pancreatic cancer.

Home | Impressum | Über SciDok | Policy | Kontakt | Datenschutzerklärung | English